Vitamin D deficiency is commonly found in patients with chronic hepatitis C. The investigators hypothesize that the correction of hypovitaminosis D before the initiation of anti-HCV combination therapy and the maintenance of an optimal vitamin D status during antiviral therapy could improve the antiviral efficacy
An open-label, prospective evaluation of the efficacy of vitamin D supplementation starting 1 month before and continuing for the duration of combination therapy with pegylated interferon alpha (2a or 2b) plus ribavirin in patients with chronic viral hepatitis C genotype 1 or 4, nonresponders to a first antiviral therapy.Vitamin D supplementation is started one month before antiviral therapy in order to introduce pegylated interferon plus ribavirin in patients with optimal vitamin D status
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
32
Vitamin D on top of the standard treatment
Hôpital Pitié Salpêtrière
Paris, France
Negativity of HCV RNA below 12UI/mL after 12 weeks of antiviral combination therapy
Time frame: at week 12
Changes in HCV viral load after correction of vitamin D deficiency (delta log)
Time frame: at day 0
Changes in HCV viral load (delta log)
Time frame: at week 4
Changes in HCV viral load (delta log)
Time frame: at week 12
Negativity of HCV RNA below 12 UI/ml
Time frame: at week 24
Negativity of HCV RNA below 12 UI/ml
Time frame: at week 72
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.